Thomas Weller — Head of Drug Discovery Chemistry and Vice President at Actelion

Mr. Thomas Weller serves as the Head of Drug Discovery Chemistry and Vice President of Actelion Pharmaceuticals U.S., Inc. Mr. Weller served as the Head of Drug Discovery-Chemistry and Vice President of Actelion Ltd. since 1999 and also served as its Member of the Management Board. Mr. Weller joined Actelion Pharmaceuticals Ltd in 2000. Mr. Weller is a Scientific expert of Leader drug discovery projects, F. Hoffmann-La Roche. He spent 16 years in the drug discovery unit at F. Hoffmann-La Roche as group leader and as area head of chemistry in thrombosis and arteriosclerosis. His projects included the isolation of active principles from fermentation broths, medicinal chemistry on PAF antagonists, thrombin inhibitors, vitronectin receptor antagonists and oxidosqualene cyclase inhibitors. In the field of fibrinogen receptor antagonists two of his molecules, lamifiban and sibrafiban, were among the most advanced of their class and progressed through clinical development up to phase III trials. Mr. Weller is a Chemist educated at the Swiss Federal Institute of Technology (ETH) in Zurich with postdoctoral training in organic chemistry at Columbia University, New York, USA. Mr. Weller studied chemistry at the ETH Zurich and completed his PhD thesis under Professor D. Seebach with further training at Columbia University New York under Professor G. Stork.